SYDNEY Feb 12 Australian blood products maker
CSL Ltd reported a 3 percent rise in first-half net
profit, in line with market forecasts, and reaffirmed it expects
full-year growth of around 7 percent.
The bottom line for the world's no.2 blood products maker
was dented by a settlement on a U.S. antitrust class action,
which had been previously flagged.
Net profit after tax for the six months ending December 2013
rose to $646 million from A$627 million a year ago, matching
market forecasts of around $644 million. The class action
settlement cost $39 million after tax.
"Competition is vigorous but I believe our philosophy of
sustainable continuous improvement in everything we do is
fundamental to dealing with these pressures," CSL Chief
Executive Paul Perrault said in a statement.
CSL's shares closed at A$69.86 on Tuesday, up 23 percent
over the past year, against a 6 percent rise in the broader
(Reporting by Maggie Lu Yueyang; Editing by John Mair)